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ABSTRACT 
A modified diffusion/compartmental model has been used to simulate 
the transdermal uptake of clenbuterol from a matrix-type delivery device. 
The application of a fresh device every 7 days was found to produce a 
pseudo-steady state drug plasma profile after approx. three changes of 
device. Of the matrix properties, only drug loading had substantial effect on 
the drug plasma profile. 
INTRODUCTION 
Drugs having long pharmacokinetic half-lives are considered to be 
unsuitable for transdermal application, owing to the prolonged times (tm ) 
necessary before drug plasma levels achieve a pseudo-steady state (1). An 
example is the 0-2 adrenergic agonist, clenbuterol, which has a half life of 
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20-35 h after i.v. injection (2). The topical application of this drug from a 
matrix-type transdermal device has been previously analyzed using a 
combined diffusion/compartmental model for transdermal drug uptake. 
Application of the model to some in vivo data obtained for a single device 
worn for 7 days showed that a tmax of some 21 days could be expected with 
this drug (3). Simulations showed that this extended tmax could not be 
reduced substantially by altering either the properties of the matrix device or 
the permeability of the stratum corneum with a permeation enhancer. 
Further simulations with a model for transdermal drug uptake from a 
membrane-controlled-type device (4) illustrated the possibility of reducing 
tmax by incorporating a 'loading dose' of drug into the rate-controlling 
membrane. 
Matrix-type devices are, however, advantageous by virtue of their 
simple construction. For this reason, our attention turned to an examination 
of the repeated application of such a device over a prolonged period. We 
wished to determine if an acceptable drug plasma profile could be obtained 
in this way by varying the properties of the device or those of the stratum 
corneum. The results are presented in this paper. 
THEORY 
For this study we took a combined, non-steady state 
diffusion/compartmental model for transdermal drug delivery from a matrix-
type device (3). To allow for the effects of application of a fresh device 
every 7 days, it was necesssary to introduce a parallel pathway into the 
model (Fig. 1). Thus, pathway I represents uptake of drug from the current 
matrix, whereas pathway II allows for the drug residue still existing in the 
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FIGURE 1 
M o d i f i e d diffusion/compartmental model f o r 
repeated a p p l i c a t i o n of a matrix-type device. 
system from the previous matrix. With the help of this model it was possible 
to produce simulated plasma profiles for clenbuterol in a matrix prepared 
from Eudragit NE30D. Values for the various system constants were taken 
from the literature (3,5). The effects on the plasma profiles of changing drug 
loading of the matrix, matrix thickness, drug diffusivity in the matrix, and 
drug diffusivity in the stratum corneum were simulated. In this way, we 
hoped to determine if the transdermal application of clenbuterol from such 
a device was at all feasible. 
RESULTS AND DISCUSSION 
The influence of drug loading of the matrix on the plasma profile is 
simulated in Fig. 2. As a result of the non-sink, non-steady state nature of 
the model, the plasma profile for each application of a matrix shows a lag 
phase, after which the drug concentration climbs to a maximum, and then 
declines. A 'pseudo-steady state' plateau is achieved during application of 
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the third device. The oscillation of the plasma profile is damped in this 
phase, owing to the existence of a drug 'depot' within the stratum corneum. 
This reduces the influence of the lag time for drug passage through the 
stratum corneum. The drug loading clearly has a large influence on the 
plasma profile. With 8% loading, the plasma profile lies well within the 
required therapeutic concentration for clenbuterol of approx. 100 pg/ml (5). 
The diffusivity of the drug within the device has much less influence 
on the plasma profile (Fig. 3). Indeed, an increase of an order of magnitude 
hardly changes the profile. The thickness of the device has no discernable 
influence on the profile (Fig. 4), as known from previous work (3,6). The 
only device property which can effectively be used to adjust the plasma 
profile is, therefore, drug loading. This will, however, be limited by the 
solubility of the drug in the matrix. 
The influence of diffusivity within the stratum corneum on the plasma 
profile (Fig. 5) shows clearly that the complete process is strongly dependent 
on the properties of this membrane. A change of an order of magnitude has 
great influence on the plasma profile. This could clearly be a source of 
considerable variation in plasma profiles between patients or between 
different body sites. 
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